Biosimilars for aflibercept and ranibizumab in development
Formycon is solidifying its position in ophthalmologic follow-on products with the development of a biosimilar for aflibercept. It joins the follow-on version of ranibizumab that is already in Phase 3 clinical trials.
Powered by Steuernachrichten
Our Industry Partners
Empowering Excellence in Ophthalmology
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.
West Virginia Academy of Eye Physicians and Surgeons — advancing quality eye care through education, advocacy, and community awareness.
About
Resources
Advocacy